Solid lipid nanoparticles: a novel approach to improve the therapeutic efficacy of glimepiride in diabetes management
Doi: https://doi.org/10.55522/ijti.v4i4.0166
DOI:
https://doi.org/10.55522/Keywords:
- Solid lipid nanoparticles, Glimepiride, Diabetes mellitus, Nanocarrier, Bioavailability, Controlled release, BCS Class II.
Abstract
Glimepiride is a third-generation sulfonylurea drug widely used for the treatment of type 2 diabetes mellitus and has major formulation problems due to its poor aqueous solubility (BCS Class II drug). This review critically discusses the development and evaluation of Solid Lipid Nanoparticles (SLNs) as a promising nanocarrier system to overcome the bioavailability limitations of glimepiride. SLNs have several distinct advantages such as improved solubility, controlled release of the drug, enhanced stability and the possibility of targeted delivery. This review highlights the recent formulation approaches, characterisation methods and in vitro/in vivo performance of glimepiride-loaded SLN-based delivery systems, showing their potential to enhance the pharmacokinetic profile and therapeutic efficacy of glimepiride. These results underpin the potential of lipid nanotechnology to revolutionise the management of diabetes by overcoming the inherent limitations of conventional oral antidiabetic therapy.
